Table 3 Overall response rates and overall survival of the cohort according to KRAS allelic status
From: Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Response to chemotherapy | KRAS WT N = 19 | KRASbal N = 108 | KRASmin N = 95* | KRASmaj N = 45 | p |
|---|---|---|---|---|---|
Complete response | 0 | 1 (1%) | 0 | 0 | |
Partial response | 5 (26%) | 34 (31%) | 27 (28%) | 5 (11%) | |
Stable disease | 5 (26%) | 49 (45%) | 30 (32%) | 16 (36%) | |
Progressive disease | 5 (26%) | 6 (6%) | 22 (23%) | 17 (38%) | |
NE | 4 (21%) | 19 (18%) | 16 (17%) | 7 (16%) | |
ORR | 26% | 32% | 28% | 11% | 0.047* |
Median OS (months) | |||||
8.5 | 11.2 | 8.8 | 6.4 | 0.0013 | |
95% CI 7–15 | 95% CI 9.6–13 | 95% CI 7.4–10.7 | 95% CI 4.6–9.2 | ||
